BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Treatment with fibronectin also led to a reduction of oncogene transcript levels in 2/4 (50%) recipients of human BCR-ABL1+ and 4/5 (80%) recipients of BCR-ABL1T315I+ CML cells (Fig. 7m).